INCY Stock Analysis — Incyte Corporation
Sector: Healthcare
AI Verdict
At 12.6x next year's earnings for 29.0% expected EPS growth, this is cheap for the growth on offer if Incyte's drug pipeline keeps delivering.
Competitive Moat
Incyte specializes in small-molecule drugs for oncology and rare diseases, with a defensible moat built on proprietary compounds like Jakafi and a robust pipeline targeting hard-to-treat cancers. Its established expertise in kinase inhibition and ongoing clinical trial network create high barriers for generic competitors.
Summary
Incyte's stock is in focus after a 64.16% one-year return and a forward P/E of just 12.6x despite nearly 30% expected EPS growth.
Where It Stands
Shares are up 64.16% over the past year, RSI is elevated at 69.0 (pullback risk), and the stock trades at 12.6x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 69 — Near Overbought
- Trailing P/E: 16.2x
- Forward P/E: 12.6x
- PEG Ratio: 0.53
- Earnings Growth: +0.3%
- Revenue Growth: +0.2%
- Market Cap: $23.0B
- 1-Year Return: 64.16%
- 52-Week High: $118.97
- 52-Week Low: $67.17
Analyst Consensus
17 Buy · 16 Hold · 0 Sell (33 analysts)
Bull Case
With analysts expecting 29.0% EPS growth and a forward P/E of 12.6x, you're getting rapid earnings expansion at a discount to the sector.
Bear Case
An RSI of 69.0 signals overbought territory, so a typical pullback to neutral (RSI 50–65) could mean a 10–15% drop from current levels even if fundamentals remain intact.
Catalyst to Watch
Upcoming clinical trial readouts or FDA approvals for pipeline drugs could drive another re-rating if positive, or trigger a correction if results disappoint.